DK1023107T3 - Fremgangsmåde til indgivelse af farmaceutiske præparater og nucleinsyrer i skeletmuskulaturen - Google Patents

Fremgangsmåde til indgivelse af farmaceutiske præparater og nucleinsyrer i skeletmuskulaturen

Info

Publication number
DK1023107T3
DK1023107T3 DK98909691T DK98909691T DK1023107T3 DK 1023107 T3 DK1023107 T3 DK 1023107T3 DK 98909691 T DK98909691 T DK 98909691T DK 98909691 T DK98909691 T DK 98909691T DK 1023107 T3 DK1023107 T3 DK 1023107T3
Authority
DK
Denmark
Prior art keywords
muscle
nucleic acids
skeletal muscle
administration
pharmaceutical compositions
Prior art date
Application number
DK98909691T
Other languages
Danish (da)
English (en)
Inventor
Terje Lomo
Iacob Mathiesen
Original Assignee
Electrofect As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Electrofect As filed Critical Electrofect As
Application granted granted Critical
Publication of DK1023107T3 publication Critical patent/DK1023107T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/20—Applying electric currents by contact electrodes continuous direct currents
    • A61N1/205—Applying electric currents by contact electrodes continuous direct currents for promoting a biological process
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/325—Applying electric currents by contact electrodes alternating or intermittent currents for iontophoresis, i.e. transfer of media in ionic state by an electromotoric force into the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
    • A61N1/36014—External stimulators, e.g. with patch electrodes
    • A61N1/36017—External stimulators, e.g. with patch electrodes with leads or electrodes penetrating the skin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Radiology & Medical Imaging (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Electrotherapy Devices (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
DK98909691T 1997-04-03 1998-04-03 Fremgangsmåde til indgivelse af farmaceutiske præparater og nucleinsyrer i skeletmuskulaturen DK1023107T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US4259497P 1997-04-03 1997-04-03

Publications (1)

Publication Number Publication Date
DK1023107T3 true DK1023107T3 (da) 2006-12-27

Family

ID=21922760

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98909691T DK1023107T3 (da) 1997-04-03 1998-04-03 Fremgangsmåde til indgivelse af farmaceutiske præparater og nucleinsyrer i skeletmuskulaturen

Country Status (16)

Country Link
US (1) US6110161A (ja)
EP (1) EP1023107B1 (ja)
JP (2) JP2001520537A (ja)
KR (1) KR100427786B1 (ja)
CN (1) CN1198665C (ja)
AT (1) ATE337794T1 (ja)
AU (1) AU733628B2 (ja)
CA (1) CA2285056C (ja)
DE (1) DE69835761T2 (ja)
DK (1) DK1023107T3 (ja)
EA (1) EA002087B1 (ja)
ES (1) ES2273408T3 (ja)
IL (1) IL132103A0 (ja)
NO (1) NO327806B1 (ja)
NZ (1) NZ337853A (ja)
WO (1) WO1998043702A2 (ja)

Families Citing this family (125)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5993434A (en) * 1993-04-01 1999-11-30 Genetronics, Inc. Method of treatment using electroporation mediated delivery of drugs and genes
US5702359A (en) * 1995-06-06 1997-12-30 Genetronics, Inc. Needle electrodes for mediated delivery of drugs and genes
US6261281B1 (en) * 1997-04-03 2001-07-17 Electrofect As Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells
HUP0004728A3 (en) 1997-06-30 2003-08-28 Centre Nat Rech Scient Improved method for transferring nucleic acid into multicelled eukaryotic organism cells and combination therefor
DE69826124T3 (de) * 1997-06-30 2007-10-11 Institut Gustave Roussy Verabreichung der nukleinsäure in den quergestreiften muskel
US6241701B1 (en) 1997-08-01 2001-06-05 Genetronics, Inc. Apparatus for electroporation mediated delivery of drugs and genes
US6055453A (en) 1997-08-01 2000-04-25 Genetronics, Inc. Apparatus for addressing needle array electrodes for electroporation therapy
US20040229363A1 (en) * 1998-06-24 2004-11-18 Ed Nolan High efficiency transfection based on low electric field strength, long pulse length
US6678556B1 (en) 1998-07-13 2004-01-13 Genetronics, Inc. Electrical field therapy with reduced histopathological change in muscle
US7922709B2 (en) 1998-07-13 2011-04-12 Genetronics, Inc. Enhanced delivery of naked DNA to skin by non-invasive in vivo electroporation
EP1100579B1 (en) 1998-07-13 2015-09-02 Inovio Pharmaceuticals, Inc. Skin and muscle-targeted gene therapy by pulsed electrical field
CA2361601A1 (en) * 1999-02-08 2000-08-10 Cheryl Goldbeck Electrically-mediated enhancement of dna vaccine immunity and efficacy in vivo
US6593130B1 (en) 1999-04-16 2003-07-15 The Regents Of The University Of California Method and apparatus for ex vivo and in vivo cellular electroporation of gene protein or drug therapy
BR0108959A (pt) * 2000-03-03 2003-10-14 Valentis Inc Composições de polox‰mero ou poloxamina melhoradas para distribuição de ácido nucléico
JP2004532654A (ja) 2000-05-22 2004-10-28 マーク・アンド・カンパニー・インコーポレイテッド 薬剤投与システム性能評価システム及び方法
US6733485B1 (en) 2001-05-25 2004-05-11 Advanced Bionics Corporation Microstimulator-based electrochemotherapy methods and systems
US20040204669A1 (en) * 2001-07-05 2004-10-14 Hofmann Gunter A. Apparatus for electroporation mediated delivery for drugs and genes
US7713740B2 (en) * 2001-08-24 2010-05-11 University Of South Florida Method of using electric fields to facilitate the entry of molecules into cells in vivo
AU2002337840B2 (en) 2001-10-11 2007-08-09 Msd Italia S.R.L. Hepatitis C virus vaccine
ES2344253T3 (es) 2001-10-11 2010-08-23 MERCK SHARP & DOHME CORP. Vacuna contra el virus de la hepatitis c.
CA2465476A1 (en) * 2001-11-08 2003-05-15 The Regents Of The University Of California Methods and compositions for correction of cardiac conduction disturbances
MXPA04005770A (es) * 2001-12-14 2005-05-17 Genetronics Inc Metodos para la inmunizacion con polinucleotidos asistida por particulas utilizando un campo electrico de impulsos.
AU2003201093A1 (en) * 2002-01-18 2003-07-30 Inovio As Bispecific antibody dna constructs for intramuscular administration
US20050154434A1 (en) 2002-03-07 2005-07-14 Adam Simon Clinical syringe with electrical stimulation aspects
US8209006B2 (en) 2002-03-07 2012-06-26 Vgx Pharmaceuticals, Inc. Constant current electroporation device and methods of use
US7245963B2 (en) * 2002-03-07 2007-07-17 Advisys, Inc. Electrode assembly for constant-current electroporation and use
US6912417B1 (en) * 2002-04-05 2005-06-28 Ichor Medical Systmes, Inc. Method and apparatus for delivery of therapeutic agents
JP4499427B2 (ja) 2002-04-16 2010-07-07 サイト パルス サイエンシズ、インコーポレイテッド 電場の移動及び電極極性の反転で生体材料を処理する方法。
US20040106896A1 (en) * 2002-11-29 2004-06-03 The Regents Of The University Of California System and method for forming a non-ablative cardiac conduction block
US7328064B2 (en) 2002-07-04 2008-02-05 Inovio As Electroporation device and injection apparatus
EP3466483A1 (en) 2004-03-08 2019-04-10 Ichor Medical Systems Inc. Improved apparatus for electrically mediated delivery of therapeutic agents
TW200613554A (en) 2004-06-17 2006-05-01 Wyeth Corp Plasmid having three complete transcriptional units and immunogenic compositions for inducing an immune response to HIV
CA2598134A1 (en) 2005-03-19 2006-09-28 The Regents Of The University Of California Ultra low strength electric field network-mediated ex vivo gene, protein and drug delivery in cells
CA2610919C (en) 2005-06-17 2013-09-10 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Hepatitis c virus nucleic acid vaccine
DK1984007T3 (en) * 2006-02-13 2015-12-07 Oncolytics Biotech Inc Application of Low-dose local immunosuppression for amplification of viral oncolytic therapy
EP2091558B1 (en) 2006-11-17 2018-04-04 Genetronics, Inc. Methods of enhancing immune response using electroporation-assisted vaccination and boosting
PL2222697T3 (pl) 2007-11-01 2013-05-31 Astellas Pharma Inc Immunosupresyjne polipeptydy i kwasy nukleinowe
ES2588738T3 (es) * 2008-04-04 2016-11-04 The Trustees Of The University Of Pennsylvania Secuencias de consenso de proteínas del virus Chikungunya, moléculas de ácido nucleico que las codifican, y composiciones y métodos de uso de las mismas
CA2720168C (en) * 2008-04-04 2024-04-30 David B. Weiner Vaccines and immunotherapeutics using il-28 and compositions and methods of using the same
EP2147697A1 (en) 2008-07-21 2010-01-27 Centre National De La Recherche Scientifique-CNRS Process and device for applying electric fields into conductive material
EP2156860A1 (en) 2008-08-20 2010-02-24 Centre National De La Recherche Scientifique-CNRS Method for producing insulated electrodes for applying electric fields into conductive material
US20100298697A1 (en) * 2009-05-19 2010-11-25 Medtronic, Inc. Method and devices for improved efficiency of rna delivery to cells
US8207138B2 (en) 2009-05-19 2012-06-26 Medtronic, Inc. Methods and devices for improved efficiency of RNA delivery to cells
KR20120093163A (ko) 2009-09-14 2012-08-22 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 Ｉｌ-15 수용체 알파 및/또는 이를 인코딩하는 핵산 분자를 포함하는 백신 및 면역 치료제, 및 이를 이용하는 방법
CA2777705C (en) 2009-11-02 2019-03-12 The Trustees Of The University Of Pennsylvania Foot and mouth disease virus (fmdv) consensus proteins, coding sequences therefor and vaccines made therefrom
US8298820B2 (en) 2010-01-26 2012-10-30 The Trustees Of The University Of Pennsylvania Influenza nucleic acid molecules and vaccines made therefrom
EP2539354B1 (en) 2010-02-08 2017-04-05 The Trustees Of The University Of Pennsylvania Nucleic acid molecules encoding rantes, and compositions comprising and methods of using the same
KR101891195B1 (ko) 2010-09-27 2018-08-24 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 공통 항원 구성체 및 이것으로부터 만들어진 백신 및 말라리아를 치료하기 위한 이것의 사용방법
CN103314002B (zh) 2010-11-12 2016-09-07 宾夕法尼亚大学托管会 共有前列腺抗原、编码所述抗原的核酸分子以及包含所述核酸分子的疫苗及其用途
US9243041B2 (en) 2011-01-31 2016-01-26 The Trustees Of The University Of Pennsylvania Nucleic acid molecules encoding novel herpes antigens, vaccine comprising the same, and methods of use thereof
US9238679B2 (en) 2011-02-11 2016-01-19 The Trustees Of The University Of Pennslyvania Nucleic acid molecule encoding hepatitis B virus core protein and surface antigen protein and vaccine comprising the same
CA2827080C (en) 2011-02-11 2022-09-20 The Trustees Of The University Of Pennsylvania Nucleic acid molecule encoding hepatitis b virus core protein and vaccine comprising the same
CN103717249B (zh) 2011-06-15 2017-03-22 克洛恩泰克制药股份公司 注射针和装置
CA2841852C (en) 2011-07-11 2020-06-30 Inovio Pharmaceuticals, Inc. Cross-protective arenavirus vaccines and their method of use
AU2012352455B2 (en) 2011-12-12 2016-01-21 The Trustees Of The University Of Pennsylvania Proteins comprising MRSA PBP2a and fragments thereof, nucleic acids encoding the same, and compositions and their use to prevent and treat MRSA infections
EP2791157A4 (en) 2011-12-12 2015-10-14 Univ Pennsylvania COMPOSITIONS WITH IMPROVED GENETIC IL-12 CONSTRUCTS AND VACCINES, IMMUNOTHERAPY THEREOF AND METHOD OF USE THEREOF
AU2013245950B2 (en) 2012-04-10 2016-04-21 The Trustees Of The University Of Pennsylvania Human respiratory syncytial virus consensus antigens, nucleic acid constructs and vaccines made therefrom, and methods of using same
KR102146904B1 (ko) 2012-04-12 2020-08-24 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 필로바이러스 공통 항원, 이로부터 제조된 핵산 구조체 및 백신, 및 이를 사용하는 방법
DE102012013534B3 (de) 2012-07-05 2013-09-19 Tobias Sokolowski Vorrichtung für repetitive Nervenstimulation zum Abbau von Fettgewebe mittels induktiver Magnetfelder
WO2014064534A2 (en) 2012-10-05 2014-05-01 Chrontech Pharma Ab Injection needle, device, immunogenic compositions and method of use
WO2014093886A1 (en) 2012-12-13 2014-06-19 The Trustees Of The University Of Pennsylvania Wt1 vaccine
MX2015011487A (es) 2013-03-15 2016-02-03 Univ Pennsylvania Proteinas de consenso para el virus de la enfermedad de la fiebre aftosa (fmdv), secuencias de codificacion para estas y vacunas elaboradas a partir de estas.
KR20150130284A (ko) 2013-03-15 2015-11-23 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 암 백신 및 이를 이용한 치료 방법
JP6692294B2 (ja) 2013-07-31 2020-05-13 バイオベンチャーズ・リミテッド・ライアビリティ・カンパニーＢｉｏＶｅｎｔｕｒｅｓ， ＬＬＣ 腫瘍関連糖鎖抗原を標的として癌を治療及び予防するための組成物及び方法
CN105829341A (zh) 2013-12-13 2016-08-03 宾夕法尼亚大学理事会 Dna抗体构建体及其使用方法
MX2017007187A (es) 2014-12-01 2018-01-30 Univ Pennsylvania Construcciones de anticuerpos de adn y metodo para utilizarlas.
US11491342B2 (en) 2015-07-01 2022-11-08 Btl Medical Solutions A.S. Magnetic stimulation methods and devices for therapeutic treatments
US11266850B2 (en) 2015-07-01 2022-03-08 Btl Healthcare Technologies A.S. High power time varying magnetic field therapy
US20180001107A1 (en) 2016-07-01 2018-01-04 Btl Holdings Limited Aesthetic method of biological structure treatment by magnetic field
US10695575B1 (en) 2016-05-10 2020-06-30 Btl Medical Technologies S.R.O. Aesthetic method of biological structure treatment by magnetic field
WO2017055522A1 (en) 2015-09-29 2017-04-06 Academisch Medisch Centrum Stabilized env proteins of hiv
US11253717B2 (en) 2015-10-29 2022-02-22 Btl Healthcare Technologies A.S. Aesthetic method of biological structure treatment by magnetic field
KR20180108793A (ko) 2016-02-05 2018-10-04 이노비오 파마수티컬즈, 인크. 암 백신 및 이를 이용하는 치료 방법
JP6910075B2 (ja) 2016-03-28 2021-07-28 イコル メディカル システムズ，インク． 治療薬の送達のための方法および装置
JP7250520B2 (ja) 2016-04-13 2023-04-03 ヤンセン ファーマシューティカルズ，インコーポレーテッド 組換えアルテリウイルスレプリコン系およびその使用
US11464993B2 (en) 2016-05-03 2022-10-11 Btl Healthcare Technologies A.S. Device including RF source of energy and vacuum system
US11247039B2 (en) 2016-05-03 2022-02-15 Btl Healthcare Technologies A.S. Device including RF source of energy and vacuum system
US11534619B2 (en) 2016-05-10 2022-12-27 Btl Medical Solutions A.S. Aesthetic method of biological structure treatment by magnetic field
US10583287B2 (en) 2016-05-23 2020-03-10 Btl Medical Technologies S.R.O. Systems and methods for tissue treatment
US10556122B1 (en) 2016-07-01 2020-02-11 Btl Medical Technologies S.R.O. Aesthetic method of biological structure treatment by magnetic field
BR112019007433A2 (pt) 2016-10-17 2019-07-02 Synthetic Genomics Inc sistemas de replicon de vírus recombinante e usos dos mesmos
EP3548625A2 (en) 2016-12-05 2019-10-09 Synthetic Genomics, Inc. Compositions and methods for enhancing gene expression
US11344618B2 (en) 2017-08-26 2022-05-31 Academisch Medisch Centrum HIV envelope glycoprotein immunogens
KR102560562B1 (ko) 2017-12-13 2023-07-31 이노비오 파마수티컬즈, 인크. Muc16을 표적화하는 암 백신 및 이의 용도
PL3737397T3 (pl) 2017-12-13 2023-03-27 Inovio Pharmaceuticals, Inc. Szczepionki przeciwnowotworowe ukierunkowane do prame i ich zastosowania
CA3083528C (en) 2017-12-13 2023-09-12 Inovio Pharmaceuticals, Inc. Cancer vaccines targeting mesothelin and uses thereof
CA3086325A1 (en) 2017-12-19 2019-06-27 Janssen Sciences Ireland Unlimited Company Methods and compositions for inducing an immune response against hepatitis b virus (hbv)
US11021692B2 (en) 2017-12-19 2021-06-01 Janssen Sciences Ireland Unlimited Company Hepatitis B virus (HBV) vaccines and uses thereof
CA3086327A1 (en) 2017-12-19 2019-06-27 Janssen Sciences Ireland Unlimited Company Hepatitis b virus (hbv) vaccines and uses thereof
US11020476B2 (en) 2017-12-19 2021-06-01 Janssen Sciences Ireland Unlimited Company Methods and compositions for inducing an immune response against Hepatitis B Virus (HBV)
US11389531B2 (en) 2017-12-19 2022-07-19 Janssen Sciences Ireland Unlimited Company Methods and apparatus for the delivery of hepatitis B virus (HBV) vaccines
AU2019210189A1 (en) 2018-01-19 2020-08-06 Janssen Pharmaceuticals, Inc. Induce and enhance immune responses using recombinant replicon systems
EP4066887B1 (en) 2019-04-11 2023-11-01 BTL Medical Solutions a.s. Devices for aesthetic treatment of biological structures by radiofrequency and magnetic energy
WO2020255042A1 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and a pyrimidine derivative
WO2020255022A1 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and aminopyridine derivatives as hpk1 inhibitors
EP3986915A1 (en) 2019-06-18 2022-04-27 Janssen Sciences Ireland Unlimited Company Recombinant interleukin 12 construct and uses thereof
WO2020255017A1 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and dihydropyrimidine derivatives as capsid assembly modulators
WO2020255015A1 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and dihydropyrimidine derivatives as capsid assembly modulators
CA3141238A1 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Hepatitis b virus (hbv) vaccines and uses thereof
WO2020255009A2 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and anti-pd-1 antibody
US20220233684A1 (en) 2019-06-18 2022-07-28 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and pd-l1 inhibitors
CA3140588A1 (en) 2019-06-18 2020-12-24 Helen Horton Combination of hepatitis b virus (hbv) vaccines and small molecule pdl1 or pd1 inhibitor
CN114630675A (zh) 2019-06-18 2022-06-14 爱尔兰詹森科学公司 乙型肝炎病毒(hbv)疫苗和抗pd-1或抗pd-l1抗体的组合
KR20220042116A (ko) 2019-06-18 2022-04-04 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 B형 간염 바이러스(HBV) 백신 및 HBV-타케팅 RNAi의 조합
WO2020255039A1 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and quinazoline derivatives
WO2020255016A1 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and dihydropyrimidine derivatives as capsid assembly modulators
WO2020255013A1 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and capsid assembly modulators being amide derivatives
WO2020254876A1 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Virus-like particle delivery of hepatitis b virus (hbv) vaccines
US20220305115A1 (en) 2019-06-18 2022-09-29 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and pyridopyrimidine derivatives
EP3986456A1 (en) 2019-06-18 2022-04-27 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and hbv-targeting rnai
WO2020255019A1 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and a quinazoline derivative
WO2020255010A1 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Combination of recombinant interleukin 12 construct and hepatitis b virus (hbv) vaccines
WO2020255035A1 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and pyrimidine derivatives
US20220305116A1 (en) 2019-06-18 2022-09-29 Janssen Sciences lreland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and capsid assembly modulators being sulfonamide derivatives
AU2020295807A1 (en) 2019-06-20 2022-02-17 Janssen Sciences Ireland Unlimited Company Lipid nanoparticle or liposome delivery of hepatitis B virus (HBV) vaccines
MA56534A (fr) 2019-06-20 2022-04-27 Janssen Sciences Ireland Unlimited Co Administration par nanoporteurs glucidiques, de vaccins contre le virus de l'hépatite b (vhb)
EP4146335A1 (en) 2020-05-04 2023-03-15 BTL Healthcare Technologies a.s. Device and method for unattended treatment of a patient
US11878167B2 (en) 2020-05-04 2024-01-23 Btl Healthcare Technologies A.S. Device and method for unattended treatment of a patient
CA3181680A1 (en) 2020-06-12 2021-12-16 University Of Rochester Encoding and expression of ace-trnas
CN116367854A (zh) 2020-07-08 2023-06-30 杨森科学爱尔兰无限公司 针对hbv的rna复制子疫苗
WO2022133230A1 (en) 2020-12-18 2022-06-23 Janssen Pharmaceuticals, Inc. Combination therapy for treating hepatitis b virus infection
EP4267740A1 (en) 2020-12-28 2023-11-01 Arcturus Therapeutics, Inc. Transcription activator-like effector nucleases (talens) targeting hbv
US11896816B2 (en) 2021-11-03 2024-02-13 Btl Healthcare Technologies A.S. Device and method for unattended treatment of a patient
WO2023150753A1 (en) 2022-02-07 2023-08-10 University Of Rochester Optimized sequences for enhanced trna expression or/and nonsense mutation suppression
WO2023233290A1 (en) 2022-05-31 2023-12-07 Janssen Sciences Ireland Unlimited Company Rnai agents targeting pd-l1

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5389069A (en) * 1988-01-21 1995-02-14 Massachusetts Institute Of Technology Method and apparatus for in vivo electroporation of remote cells and tissue
US5501662A (en) * 1992-05-22 1996-03-26 Genetronics, Inc. Implantable electroporation method and apparatus for drug and gene delivery
US5304120A (en) * 1992-07-01 1994-04-19 Btx Inc. Electroporation method and apparatus for insertion of drugs and genes into endothelial cells
US5273525A (en) * 1992-08-13 1993-12-28 Btx Inc. Injection and electroporation apparatus for drug and gene delivery
US5318514A (en) * 1992-08-17 1994-06-07 Btx, Inc. Applicator for the electroporation of drugs and genes into surface cells
US5468223A (en) * 1992-11-30 1995-11-21 C.N.R.S. Paris Electrochemotherapy
FR2703253B1 (fr) * 1993-03-30 1995-06-23 Centre Nat Rech Scient Applicateur d'impulsions electriques pour traitement de tissus biologiques.
US5702359A (en) * 1995-06-06 1997-12-30 Genetronics, Inc. Needle electrodes for mediated delivery of drugs and genes
US5993434A (en) * 1993-04-01 1999-11-30 Genetronics, Inc. Method of treatment using electroporation mediated delivery of drugs and genes
IL108775A (en) * 1994-02-25 2003-09-17 Univ Ramot Method for efficient incorporation of molecules into cells
JPH10502858A (ja) * 1995-05-02 1998-03-17 フィリップス エレクトロニクス エヌ ベー 対象の磁気共鳴画像化方法及び装置
US5944710A (en) * 1996-06-24 1999-08-31 Genetronics, Inc. Electroporation-mediated intravascular delivery
HUP0004728A3 (en) * 1997-06-30 2003-08-28 Centre Nat Rech Scient Improved method for transferring nucleic acid into multicelled eukaryotic organism cells and combination therefor

Also Published As

Publication number Publication date
DE69835761T2 (de) 2007-09-13
ES2273408T3 (es) 2007-05-01
AU6990698A (en) 1998-10-22
IL132103A0 (en) 2001-03-19
CA2285056A1 (en) 1998-10-08
EA002087B1 (ru) 2001-12-24
WO1998043702A2 (en) 1998-10-08
KR100427786B1 (ko) 2004-04-30
JP2006061701A (ja) 2006-03-09
CN1198665C (zh) 2005-04-27
EP1023107A1 (en) 2000-08-02
CA2285056C (en) 2004-12-14
DE69835761D1 (de) 2006-10-12
US6110161A (en) 2000-08-29
NO994820D0 (no) 1999-10-04
EP1023107B1 (en) 2006-08-30
EA199900882A1 (ru) 2001-02-26
CN1276740A (zh) 2000-12-13
NZ337853A (en) 2002-03-28
JP2001520537A (ja) 2001-10-30
KR20010005932A (ko) 2001-01-15
AU733628B2 (en) 2001-05-17
NO994820L (no) 1999-12-03
NO327806B1 (no) 2009-09-28
ATE337794T1 (de) 2006-09-15

Similar Documents

Publication Publication Date Title
DK1023107T3 (da) Fremgangsmåde til indgivelse af farmaceutiske præparater og nucleinsyrer i skeletmuskulaturen
ATE275423T1 (de) Verabreichung der nukleinsäure in den quergestreiften muskel
AR017866A1 (es) Metodo para incrementar las inmunorespuestas de vacunas de acidos nucleicos, composiciones farmaceuticas de aplicacion en dicho metodo, procedimientopara preparar dichas composiciones y vacunas utilizadas en dicho metodo.
DK0939590T3 (da) Nukleinsyre til anvendelse i genterapi, der involverer ekspression af tarmcellegener
ATE332725T1 (de) Verfahren zur elektropermeabilisation einzelner zellulärer und organeller strukturen
ATE323169T1 (de) Plasmid zur verabreichung von nukleine säuren und verwendungsverfahren
DE69230993T2 (de) Rekombinante viren vektoren zur expression in muskelzellen
DE60040156D1 (de) Vorrichtung zur elektroporation von genen, proteinen oder zur verabreichung von medikamenten
DE60029829D1 (de) Zelldurchlässige peptide zur inhibierung von entzündungsreaktionen und deren verwendung
DE69837274D1 (de) Verfahren zur verkapselung von nukleinsäuren in lipiddoppelschichten
CA2087087C (en) Molecules for iontophoretic delivery
EA200100856A1 (ru) Способ инкапсулирования биологически активных комплексов в липосомы
WO2003099225A3 (en) Compositions for delivering nucleic acids to cells
ATE530659T1 (de) Modulare transfektionssysteme auf der basis von nukleoproteinfilamenten
ATE88500T1 (de) Dna-sequenzen, die fuer proteine mit der biologischen aktivitaet der husi-typi-inhibitoren codieren, gentechnologische verfahren zur herstellung dieser proteine und diese proteine enthaltende arzneimittel.
IS2318B (is) Aðferðir og lyfjablöndur til ýmiss konar læknismeðferðar þar sem notuð eru gen sem umrita seytt prótín á borð við interferón-beta
IL131436A0 (en) Compositions for treatment of disorders involving programmed cell death
ES2132027A1 (es) Desarrollo de una piel artificial mediante cultivo de queratinocitos sobre una base de fibrina y fibroblastos humanos y metodo de preparacion de esta piel para trasplante.
OA08355A (fr) Nouveaux benzamides, leur procédé de préparation et leur application dans le domaine thérapeutique.
Haqqi et al. Effect of apholate (ENT 26316; NSC 26812) on nucleic acids, total protein content & activity levels of aminotransferases (GOT, GPT), alkaline phosphatase & 5'-nucleotidase in liver of male albino rats
Zampaglione et al. Genetic vaccination by gene electro-transfer in non-human primates
FR2603040B1 (fr) Proteine, sequence d'adn, poxvirus, cellules et leur procede de culture, ainsi que les compositions pharmaceutiques les contenant, utiles dans la prevention de la schistosomose
CN1270225A (zh) Epo基因的电针转移技术
WO2004028442A3 (en) Use of excipients to increase dna uptake by swine muscle cells
BR9708855A (pt) Cromossomas artificiais, usos dos mesmos e processos para preparar cromossomas artificiais